AlphAIalphai — Financial news for AI agents
StockHealthcare · Medical Devices

$INGN

Inogen Inc

Price · $INGNvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $INGN in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $INGN in the last 30 days.

Top stories · $INGNMore →
MAY 8·Investing.com AustraliaMed

Earnings call transcript: Inogen Q1 2026 shows revenue beat, EPS miss

Inogen Inc. (INGN) reported mixed Q1 2026 results, with revenue of $85.1 million ahead of forecasts by 3.34% due to strong international sales growth, while EPS missed predictions at -$0.30 against -$0.29. Despite the EPS miss, the stock saw a modest 0.7% increase in aftermarket trading, reflecting cautious optimism driven by the revenue beat and strategic product launches like the Aurora CPAP mask. The company reaffirms its 2026 revenue guidance, expecting stronger profitability in Q2 and Q3 due to seasonal trends and continued investment in new markets and product innovation.

MAR 3·Stock Titan

[Form 4] Inogen Inc Insider Trading Activity

Inogen Inc's VP and Chief Accounting Officer, Mary E. Wright, reported several equity compensation transactions detailed in a recent Form 4 SEC filing. These included the exercise or conversion of restricted stock units into common stock, grants of common stock, and shares withheld for tax liabilities. A new grant of 8,000 restricted stock units was also awarded, vesting over several years.

MAR 3·Stock Titan

Inogen (INGN) CEO receives 90,000 RSU grant and reports tax share withholdings

Inogen Inc.'s CEO, Kevin Raymond Merrill Smith, received a grant of 90,000 restricted stock units (RSUs) on February 27, 2026, which will vest over three years. He also had performance-based and time-based RSUs vest on March 1, 2026, leading to share acquisitions and subsequent share withholdings to cover tax liabilities. This information was reported in a recent SEC Form 4 filing.

News on $INGN

All news →